TOday’s Movers: Dermira (NASDAQ:DERM) Stock Rating Reconfirmed by Analysts at H.C. Wainwright; $13 Target Price Indicates 90.06 % Potential

Dermira, Inc. (NASDAQ:DERM) Logo

Investors sentiment increased to 1.3 in Q4 2018. Its up 0.34, from 0.96 in 2018Q3. It is positive, as 4 investors sold Dermira, Inc. shares while 39 reduced holdings. 26 funds opened positions while 30 raised stakes. 36.16 million shares or 3.01% more from 35.10 million shares in 2018Q3 were reported.

Proshare Advsrs Ltd accumulated 17,931 shares or 0% of the stock. Rhumbline Advisers accumulated 0% or 46,353 shares. Swiss State Bank owns 0% invested in Dermira, Inc. (NASDAQ:DERM) for 55,700 shares. Jane Street has 13,165 shares. Eventide Asset Mgmt Ltd Llc, Massachusetts-based fund reported 334,000 shares. Bnp Paribas Arbitrage reported 15 shares stake. 493,573 are held by Jpmorgan Chase And. Benjamin F Edwards & Company Incorporated has 0% invested in Dermira, Inc. (NASDAQ:DERM) for 100 shares. State Board Of Administration Of Florida Retirement Systems reported 15,213 shares. Alliancebernstein L P reported 0% in Dermira, Inc. (NASDAQ:DERM). Parametric Portfolio Ltd Liability Co holds 0% or 82,491 shares. Plante Moran Ltd Liability Co owns 142 shares. Franklin Resources reported 2.39M shares. First Midwest Comml Bank Trust Division holds 443,625 shares. Glenmede Na reported 0% of its portfolio in Dermira, Inc. (NASDAQ:DERM).

Since October 19, 2018, it had 0 insider purchases, and 1 insider sale for $55,000 activity.

Dermira (NASDAQ:DERM) Rating Reaffirmed

Recently, In analysts report made public on Friday morning, Dermira (NASDAQ:DERM) shares have had their “Buy” Rating restate by stock research analysts at H.C. Wainwright, who currently has a $13 target on company. This target by H.C. Wainwright indicates the possibile upside of 90.06 % from the last stock price.

Dermira, Inc. (NASDAQ:DERM) Ratings Coverage

Among 5 analysts covering Dermira (NASDAQ:DERM), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Dermira has $20 highest and $9 lowest target. $15.75’s average target is 130.26% above currents $6.84 stock price. Dermira had 9 analyst reports since January 17, 2019 according to SRatingsIntel. Mizuho maintained the stock with “Hold” rating in Thursday, March 7 report. The company was maintained on Wednesday, February 27 by Mizuho. The firm has “Buy” rating given on Friday, February 22 by Leerink Swann. The stock has “Buy” rating by Cantor Fitzgerald on Thursday, February 21. The stock of Dermira, Inc. (NASDAQ:DERM) has “Market Perform” rating given on Thursday, January 17 by Raymond James. On Wednesday, February 27 the stock rating was maintained by H.C. Wainwright with “Buy”.

The stock decreased 1.01% or $0.07 during the last trading session, reaching $6.84. About 1.89 million shares traded or 140.81% up from the average. Dermira, Inc. (NASDAQ:DERM) has declined 61.94% since March 16, 2018 and is downtrending. It has underperformed by 66.31% the S&P500.

Analysts await Dermira, Inc. (NASDAQ:DERM) to report earnings on May, 2. They expect $-1.38 earnings per share, up 0.72 % or $0.01 from last year’s $-1.39 per share. After $-1.70 actual earnings per share reported by Dermira, Inc. for the previous quarter, Wall Street now forecasts -18.82 % EPS growth.

Dermira, Inc., a biopharmaceutical company, engages in identifying, developing, and commercializing therapies to enhance the lives of patients with dermatologic diseases. The company has market cap of $289.53 million. The company's pipeline includes three late-stage product candidates, such as Glycopyrronium tosylate, an anticholinergic product that is in Phase III clinical trial for the treatment of primary axillary hyperhidrosis or excessive underarm sweating; Olumacostat glasaretil, a small-molecule designed to target sebum production, following topical application is in Phase III development for the treatment of acne vulgaris; and lebrikizumab, a novel, humanized monoclonal antibody targeting interleukin 13, for which the firm is planning to initiate a Phase IIb dose-ranging study for the treatment of moderate-to-severe atopic dermatitis. It currently has negative earnings. It has a licensing agreement with Roche to develop and commercialize lebrikizumab for atopic dermatitis and other potential indications.

More notable recent Dermira, Inc. (NASDAQ:DERM) news were published by: Nasdaq.com which released: “Dermira to Present New Analyses of the Glycopyrronium Tosylate Clinical Program at the 77th American Academy of Dermatology Annual Meeting – Nasdaq” on February 26, 2019, also Nasdaq.com with their article: “Dermira Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update – Nasdaq” published on February 26, 2019, Globenewswire.com published: “Dermira to Report Fourth Quarter 2018 Results and Host Conference Call on Tuesday, February 26, 2019 – GlobeNewswire” on February 19, 2019. More interesting news about Dermira, Inc. (NASDAQ:DERM) were released by: Schaeffersresearch.com and their article: “2 Pharma Stocks Under $10 to Buy Now, Analysts Say – Schaeffers Research” published on February 14, 2019 as well as Nasdaq.com‘s news article titled: “Implied Volatility Surging for Dermira (DERM) Stock Options – Nasdaq” with publication date: March 01, 2019.

Dermira, Inc. (NASDAQ:DERM) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.